Infliximab in the treatment of psoriasis in patients previously treated with etanercept

Journal of the American Academy of Dermatology

Volumn 57, Issue 1, 2007, Pages 120-125

  Haitz, Kassie A ^a   Kalb, Robert E ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; INFLIXIMAB;

ADULT; AGED; ARTICLE; BACKACHE; CLINICAL ARTICLE; DIABETES MELLITUS; DIAPHORESIS; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG INDUCED HEADACHE; EXTERNAL OTITIS; EYE INFECTION; FATIGUE; FEMALE; HEART INFARCTION; HUMAN; MALE; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; PSORIASIS; RETROSPECTIVE STUDY; SIDE EFFECT; SINUSITIS; SKIN INFECTION; TREATMENT FAILURE; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34250214167     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2007.03.035     Document Type: Article

References (30)

1. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 14 (1996) 485-496
2. Scallon B., Cai N., Solowski N., Rosenberg A., Song X., Shealy D., et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301 (2002) 418-426
3. Tyring S, Poulin Y, Langley R, Gordon K. A 96-week phase 3 study of safety and efficacy of etanercept 50 mg twice weekly in patients with psoriasis. Poster P39 presented at: Annual Meeting of the American Academy of Dermatology; March 4, 2006; San Francisco, CA.
4. Reich K., Nestle F.O., Papp K., Ortonne J.P., Evans R., Guzzo C., et al., EXPRESS Study Investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicenter, double-blind trial. Lancet 366 (2005) 1367-1374
5. Menter A., Feldman S.R., Weinstein G., Papp K., Evans R., Guzzo C., et al. A randomized comparison of continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 56 (2007) 31.e1-31.e15
6. Gottlieb A.B., Evans R., Li S., Dooley L.T., Guzzo C.A., Baker D., et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 51 (2004) 534-542
7. Chaudhari U., Romano R., Mulcahy L.D., Dooley L.T., Baker D.G., and Gottlieb A.B. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 357 (2001) 1842-1847
8. Kalb R.E., and Gurske J. Infliximab for the treatment of psoriasis: clinical experience at the State University of New York at Buffalo. J Am Acad Dermatol 53 (2005) 616-622
9. Krathen R.A., Berthelot C.N., and Hsu S. Sustained efficacy and safety of infliximab in psoriasis: a retrospective study of 73 patients. J Drugs Dermatol 5 (2006) 251-254
10. Smith C.H., Jackson K., Bashir S.J., Perez A., Chew A.L., Powell A.M., et al. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study. Br J Dermatol 155 (2006) 160-169
11. Ahmad K., and Rogers S. Three years' experience with infliximab in recalcitrant psoriasis. Clin Exp Dermatol 31 (2006) 630-633
12. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., and Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 (2006) 2275-2285
13. Wolfe F., and Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50 (2004) 1740-1751
14. Gonzalez-Gay M.A., Garcia-Unzueta M.T., De Matias J.M., Gonzalez-Juanatey C., Garcia-Porrua C., Sanchez-Andrade A., et al. Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin Exp Rheumatol 24 (2006) 373-379
15. Dahlqvist S.R., Engstrand S., Berglin E., and Johnson O. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy. Scand J Rheumatol 35 (2006) 107-111
16. Kiortsis D.N., Mavridis A.K., Vasakos S., Nikas S.N., and Drosos A.A. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 33 (2006) 921-923
17. Allanore Y., Kahan A., Sellam J., Ekindjian O.G., and Borderie D. Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. Clin Chim Acta 365 (2006) 143-148
18. Gelfand J., Neimann A., Shin D., Wang X., Margolis D., and Troxel A. Risk of myocardial infarction in patients with psoriasis. JAMA 296 (2006) 1735-1741
19. van Vollenhoven R., Harju A., Brannemark S., and Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumor necrosis factor alpha blockers can make sense. Ann Rheum Dis 62 (2003) 1195-1198
20. Ang H.T., and Helfgott S. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis?. J Rheumatol 30 (2003) 2315-2318
21. Iannone F., Trotta F., Montecucco C., Giacomelli R., Galeazzi M., Matucci-Cerinic M., et al. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab due to side effects. Ann Rheum Dis 66 (2007) 249-252
22. Gomez-Reino J.J., and Carmona L. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 8 (2006) R29
23. Cohen G., Courvoisier N., Cohen J.D., Zaltni S., Sany J., and Combe B. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol 23 (2005) 795-800
24. van Vollenhoven R.F. Switching between biological agents. Clin Exp Rheumatol 22 Suppl (2004) S115-S121
25. Combe B. Switching between anti-TNF alpha agents: what is the evidence?. Joint Bone Spine 71 (2004) 169-171
26. Hansen K.E., Hildebrand J.P., Genovese M.C., Cush J.J., Patel S., Cooley D.A., et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 31 (2004) 1098-1102
27. Strober B, Gottlieb A, Leonardi C, Papp K. Levels of response of psoriasis patients with different baseline characteristics treated with etanercept. Poster P2890 presented at: Annual Meeting of the American Academy of Dermatology; March 4, 2006; San Francisco, CA.
28. Reich K., Gottlieb A.B., Kimball A., and Li S. Consistency of infliximab response across subgroups of patients with psoriasis: integrated results from randomized controlled clinical trials. [abstract P2871]. J Am Acad Dermatol 54 Suppl (2006) AB215
29. Bendtzen K., Geborek P., Swenson M., Larson L., Kapetanovic M.C., and Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab. Arthritis Rheum 54 (2006) 3782-3789
30. Westhovens R., Yocum D., Han J., Berman A., Strusberg I., Geusens P., et al., START Study Group. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 54 (2006) 1075-1086